David Parrot - 13 Mar 2026 Form 4 Insider Report for Scribe Therapeutics, Inc. (SCTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: SCTX
Reported as of: 13 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jul 2026, 21:20:26 UTC
Next SEC filing: 23 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ David L. Parrot

Filing notes and source

Key filing fact

David Parrot filed Form 4 for Scribe Therapeutics, Inc. (SCTX) on 27 Jul 2026.

Key facts

This page summarizes David Parrot's Form 4 filing for Scribe Therapeutics, Inc. (SCTX).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 27 Jul 2026, 21:20.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127908 Primary reporting owner

Parrot David

Relationship: Chief Financial Officer
Address: C/O SCRIBE THERAPEUTICS INC., 1150 MARINA VILLAGE PARKWAY, ALAMEDA
Signature: /s/ David L. Parrot
Signature date: 27 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +1,333
Change %
Price: $15.00^*
Shares after: 1,333
Date: 23 Jul 2026
Ownership: By Spouse

SCTX transaction

Common Stock

Purchase

Transaction value
Shares: +1,333
Change %
Price: $15.00^*
Shares after: 1,333
Date: 23 Jul 2026
Ownership: By Child

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SCTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +8,909
Change %
Price: $0.000000^*
Shares after: 8,909
Date: 13 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,909
Exercise price: $19.13
Footnotes: F1, F2

SCTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +109,426
Change %
Price: $0.000000^*
Shares after: 109,426
Date: 23 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 109,426
Exercise price: $15.00
Footnotes: F3

SCTX transaction Derivative

Performance-based Stock Option (Right to Buy)

Award

Transaction value
Shares: +109,426
Change %
Price: $0.000000^*
Shares after: 109,426
Date: 23 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 109,426
Exercise price: $15.00
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

Footnote F2

The option is fully vested.

Footnote F3

The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F4

The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.